The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: clinical experience with anti-angiogenic agents, focusing on bevacizumab.
about
Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancerModes of resistance to anti-angiogenic therapyClinical results of randomized trials and 'real-world' data exploring the impact of Bevacizumab for breast cancer: opportunities for clinical practice and perspectives for research.Vascular endothelial growth factor secreted by activated stroma enhances angiogenesis and hormone-independent growth of estrogen receptor-positive breast cancerBevacizumab based chemotherapy in first line treatment of HER2 negative metastatic breast cancer: results of a Moroccan observational institutional study.Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy.Management options in triple-negative breast cancerBevacizumab revisited: its use in different mouse models of ocular pathologies.Upregulated expression of indoleamine 2, 3-dioxygenase in primary breast cancer correlates with increase of infiltrated regulatory T cells in situ and lymph node metastasisNoncardiac vascular toxicities of vascular endothelial growth factor inhibitors in advanced cancer: a reviewDifferential microstructure and physiology of brain and bone metastases in a rat breast cancer model by diffusion and dynamic contrast enhanced MRI.Combined-modality radioimmunotherapy: synergistic effect of paclitaxel and additive effect of bevacizumabTriple-negative breast cancer: multipronged approach, single-arm pilot phase II study.A randomized, phase II, three-arm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancer.Bevacizumab in the treatment of breast cancer.Pazopanib: an antiangiogenic drug in perspective.Bevacizumab in combination with taxanes for the first-line treatment of metastatic breast cancer.Bevacizumab: a review of its use in combination with paclitaxel or capecitabine as first-line therapy for HER2-negative metastatic breast cancer.Identification and in vitro characterization of phage-displayed VHHs targeting VEGF.Anti-angiogenic agents for the treatment of solid tumors: Potential pathways, therapy and current strategies - A review.A multicenter phase II study of TSU-68, a novel oral multiple tyrosine kinase inhibitor, in patients with metastatic breast cancer progressing despite prior treatment with an anthracycline-containing regimen and taxane.Sex steroids and breast cancer metastasis.The efficacy and safety of bevacizumab combined with chemotherapy in treatment of HER2-negative metastatic breast cancer: a meta-analysis based on published phase III trials.The efficacy of bevacizumab plus paclitaxel as first-line treatment for HER2-negative metastatic breast cancer: a meta-analysis of randomized controlled trials.A multicenter phase II study of TSU-68, an oral multiple tyrosine kinase inhibitor, in combination with docetaxel in metastatic breast cancer patients with anthracycline resistance.
P2860
Q24202199-8847C70E-40C3-4EE5-AEF3-2079840985B4Q24608005-B411AD5E-D3BC-4F0E-969F-7950F860EA5EQ31157714-593175AB-FCF8-41A2-BBFB-4FBB7A16C496Q33766941-1A727955-D921-4A0D-8208-02D2F916CE26Q34206792-704261E9-7F5C-4BA0-8283-3D90694BF4E7Q34452673-85D9059C-EC55-486F-ADD4-5AF2C14A205DQ35155460-971B66F6-BFD2-4C61-A7F4-080A2C03DD49Q35223791-6AE2D430-AA2A-475F-A1C7-DF08F3EE4AFBQ35450360-C1A800D5-D50E-416A-AC32-186185C9EBDBQ35584543-2AE9CF8F-7C15-4079-80C9-BE48EEA166EDQ35600833-93DCA9F1-7721-4EDF-B36B-2C64E587D179Q35842769-DAC52B8A-11FA-4206-81F2-CA1A9AAD86BAQ36530636-D3497402-9506-4EA1-A403-EDBB6003A2ECQ36892821-42F67E3D-D250-4280-B0AF-131FAA51C8BAQ37299995-EAEE2A4A-7106-44EA-AACA-E552985CC83BQ37630567-88322B46-CB2A-4E88-A62C-C7EAA56BBB1EQ37718401-1510D613-0FD4-4279-831F-76489346CF5FQ37950522-1F06E305-DD15-4553-BD68-A448F094F328Q39051064-A89532AE-EB62-400C-919A-95D69319F7DDQ41258130-387461FD-5575-4031-92C2-1BB153015EABQ45787581-859C25CD-27D5-4D54-8B94-3C9E17652D5EQ53292930-86B9F33B-B3DC-4474-81DA-918D25FADD40Q54310257-17802978-895F-448F-86E4-B3F5F9A084F3Q54374887-FA3357E6-9465-4CAB-AF9E-21A48F7370DAQ54526078-BB17D3F3-D271-4F1D-B227-AB991F432FA5
P2860
The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: clinical experience with anti-angiogenic agents, focusing on bevacizumab.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 07 April 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The potential of anti-vascular ...... ents, focusing on bevacizumab.
@en
The potential of anti-vascular ...... ents, focusing on bevacizumab.
@nl
type
label
The potential of anti-vascular ...... ents, focusing on bevacizumab.
@en
The potential of anti-vascular ...... ents, focusing on bevacizumab.
@nl
prefLabel
The potential of anti-vascular ...... ents, focusing on bevacizumab.
@en
The potential of anti-vascular ...... ents, focusing on bevacizumab.
@nl
P1476
The potential of anti-vascular ...... gents, focusing on bevacizumab
@en
P2093
Michel Marty
P304
P356
10.1016/J.EJCA.2008.01.005
P50
P577
2008-04-07T00:00:00Z